February 2, 2023

View all on-demand sessions from the Intelligent Security Summit here.


From generative AI applications to healthcare and biotech, these are five AI startups — including three based in Israel — that made headlines last week:

1. Tome applies AI-generated text and images together for presentations.

Tome, which calls itself the “new storytelling format for work and important ideas” and last month integrated OpenAI’s DALL-E into its flexible, interactive slide options, announced this week that it has added generic “generated storytelling” to the mix . That is, with a single text prompt, the AI ​​startup says creators can “generate full stories from scratch, complete with intelligent titles, outlines, pagination, page layouts, and page content backed by GPT-3 and AI-generated graphics. .”

The capabilities have launched in beta. Additional iterations and new AI functionality are expected in early 2023, including text and tone editing, inline image adjustments, and alternate layouts, according to a press release.

2. Jasper releases Jasper Chat to create AI-generated content.

Dave Rogenmoser, CEO of AI content platform Jasper, which raised $125 million in funding in October, recently told VentureBeat that generative AI “will impact any tool.” So does Jasper: This week, the AI ​​startup announced a new AI chat interface that uses natural language that allows users to request various tasks, such as “Write a blog post on…”, “Create ad variations for…” , or make adjustments to reflect a more casual tone.

Event

Intelligent Security Summit on demand

Learn the critical role of AI and ML in cybersecurity and industry-specific case studies. Check out on-demand sessions today.

Look here

According to a press release, Jasper Chat is “built and refined for business use cases, such as marketing and sales departments…it also allows users to vote for or against all results, allowing Jasper to learn and get aligned over time.”

3. Imagen AI wins $30 million for AI-powered photo editing

Tel Aviv-based Imagen AI, a leading provider of AI-powered editing solutions for professional photographers, this week announced a $30 million investment led by global growth investor Summit Partners.

According to a press release, the AI ​​startup was founded in July 2020 to “modernize and improve the post-production workflow of professional photographers by intelligently automating image editing at scale.” Imagen’s AI technology creates an individual profile based on a photographer’s previous work and unique creative style. The more photos uploaded, with more different scenes and lighting conditions, the better the AI ​​can capture each editing style and accurately predict dozens of editing parameters. The company says its solution can save up to 90% of post-production time.

4. Healthcare startup Biomica raises $20 million

Israeli AI healthcare startup Biomica, a subsidiary of Evogene, Ltd., is a clinical-stage biotech company that uses the human microbiome to create groundbreaking life sciences products to treat a range of serious diseases. It closed a $20 million funding round this week for its predictive biology platform that uses AI and big data to determine the best strains of microbes for each patient.

The company’s first drug is currently undergoing a phase 1 trial, where it is being tested to demonstrate the effect of the gut microbiome on improving response to cancer treatment and facilitating anti-tumor immune activity.

5. AI pharmaceutical startup Quris gets a $9 million investment

Another Tel Aviv-based AI startup, Quris, has announced that it has raised an additional $9 million in seed funding, bringing its total to $37 million. The pharmaceutical startup says it is “the first bio-AI clinical prediction platform that simulates clinical trials using a patented patient-on-chip system through the use of stem cell-derived tissue and AI to predict the response of a real human.” body on drugs without relying on time-consuming, imprecise animal testing.”

The AI ​​technology, it says, better predicts which drug candidates will work safely in humans, reducing drug development costs and duration. The company aims to improve its Bio-AI platform, grow its team, strengthen industry collaborations and accelerate its research into new drugs.

VentureBeat’s mission is to become a digital city plaza where tech decision makers can learn about transformative business technology and execute transactions. Discover our Briefings.

Leave a Reply

Your email address will not be published. Required fields are marked *